Clinical Trials
23 trialsNCT03083041 2026-03-03
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03777124 2025-07-04
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT07031154 2025-06-22
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
The First Affiliated Hospital of Xiamen University
Phase 2 Not yet recruiting
NCT04379739 2023-12-06
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Active not recruiting
NCT05932264 2023-07-06
Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04749394 2022-08-16
A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy
ChineseAMS
Phase 2 Unknown
NCT04878107 2022-05-02
SABRE
Wuhan University
Phase 2 Unknown
NCT04968002 2021-07-20
Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer: A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Unknown
NCT04950400 2021-07-06
A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC
Beijing Chest Hospital
Phase NA Unknown
NCT03256721 2021-02-08
Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
Fuzhou General Hospital
Phase 2 Terminated
NCT03267654 2020-08-03
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT03758677 2020-07-23
Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation
The First Hospital of Jilin University
Phase 2 Unknown
NCT04133337 2019-10-21
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 1/2 Unknown
NCT03384511 2018-02-20
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
Phase 4 Completed
NCT03201146 2017-11-17
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
West China Hospital
Phase 1/2 Unknown
NCT02515435 2017-08-18
The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer
Tongji University
Phase 2 Unknown
NCT02332512 2017-02-24
ANSWER
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03050411 2017-02-10
Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Peking University Third Hospital
Phase 1 Unknown
NCT02780778 2016-05-23
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT02733107 2016-04-12
The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer
Third Military Medical University
Phase 2 Unknown
NCT02540824 2015-09-04
Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer
Tongji University
Phase 2 Unknown
NCT01287962 2013-12-09
Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 3 Unknown
NCT01270386 2012-02-10
A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed